These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 11851646)

  • 21. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
    Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
    Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
    Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.
    Fromm MF; Dilger K; Busse D; Kroemer HK; Eichelbaum M; Klotz U
    Br J Clin Pharmacol; 1998 Mar; 45(3):247-55. PubMed ID: 9517368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influence of rifampicin on antihypertensive effects of dihydropiridine calcium-channel blockers in four elderly patients].
    Yoshimoto H; Takahashi M; Saima S
    Nihon Ronen Igakkai Zasshi; 1996 Sep; 33(9):692-6. PubMed ID: 8940868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.
    Holtbecker N; Fromm MF; Kroemer HK; Ohnhaus EE; Heidemann H
    Drug Metab Dispos; 1996 Oct; 24(10):1121-3. PubMed ID: 8894514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of nilvadipine in plasma and urine by capillary column gas chromatography with electron-capture detection.
    Tokuma Y; Fujiwara T; Sekiguchi M; Noguchi H
    J Chromatogr; 1987 Mar; 415(1):156-62. PubMed ID: 3584351
    [No Abstract]   [Full Text] [Related]  

  • 27. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.
    Ged C; Rouillon JM; Pichard L; Combalbert J; Bressot N; Bories P; Michel H; Beaune P; Maurel P
    Br J Clin Pharmacol; 1989 Oct; 28(4):373-87. PubMed ID: 2590599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans.
    Bienvenu T; Rey E; Pons G; d'Athis P; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1991 Nov; 29(11):441-5. PubMed ID: 1800391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects.
    Saima S; Furuie K; Yoshimoto H; Fukuda J; Hayashi T; Echizen H
    Br J Clin Pharmacol; 2002 Feb; 53(2):203-6. PubMed ID: 11851646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nilvadipine: profile of a new calcium antagonist. An overview.
    Rosenthal J
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist.
    Honerjäger P; Seibel K
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S15-21. PubMed ID: 1283184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of nilvadipine.
    von Nieciecki A; Huber HJ; Stanislaus F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S22-9. PubMed ID: 1283185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
    Brogden RN; McTavish D
    Drugs Aging; 1995 Feb; 6(2):150-71. PubMed ID: 7711361
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.